AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19941990 — intervention group
Group type: EXPERIMENTAL
Intervention: CDA1 (10mg/kg intravenous infusion)
Number of subjects: 46
Study 19941990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 19941990 — intervention group
Group type: EXPERIMENTAL
Intervention: CDA1
Number of subjects: 46
Study 18188758 — intervention group
Group type: EXPERIMENTAL
Intervention: Information-only (INF)
Number of subjects: 0
Study 18188758 — intervention group
Group type: EXPERIMENTAL
Intervention: Sampling (SMP)
Number of subjects: 0
Study 16186288 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin daily
Number of subjects: 3038
Study 16186288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3038
Study 12594635 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid formulation of amphotericin B (L‐AmB), 10 mg/kg daily for 2 days
Number of subjects: 41
Study 12594635 — intervention group
Group type: COMPARATOR
Intervention: Lipid formulation of amphotericin B (L‐AmB), 4 mg/kg daily for 5 days
Number of subjects: 41
Study 12594635 — intervention group
Group type: COMPARATOR
Intervention: Meglumine antimoniate
Number of subjects: 41
Study 10556145 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin 160 mg via dry powder inhaler (DPI)
Number of subjects: 10
Study 10556145 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin via small-volume nebulizer (SVN)
Number of subjects: 10
Study 10556145 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin at 5 mg/kg by intravenous infusion
Number of subjects: 10
Study 8737325 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.25 g creatine monohydrate per kg body mass)
Number of subjects: 19
Study 8737325 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CON group)
Number of subjects: 19
Study 1376482 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized linear model fitted on VPB counts for MI survivors
Number of subjects: 0
Study 1376482 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized linear model
Number of subjects: 0
Study 1376482 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of VPB counts
Number of subjects: 0
Study 4000778 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial plasma exchange transfusion
Number of subjects: 93
Study 4000778 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment
Number of subjects: 93
Study 4000778 — intervention group
Group type: COMPARATOR
Intervention: Control infants without polycythemia
Number of subjects: 93
Study 29651970 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg per day)
Number of subjects: 60
Study 29651970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 27575717 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 131
Study 27575717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 25567010 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (HepB) administered on 0-1-6 schedule
Number of subjects: 228
Study 25567010 — intervention group
Group type: COMPARATOR
Intervention: Control group (HepB)
Number of subjects: 228
Study 25567010 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-HBc alone (HepB)
Number of subjects: 228
Study 25567010 — intervention group
Group type: COMPARATOR
Intervention: Control group (after first-dose revaccination)
Number of subjects: 228
Study 25567010 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-HBc alone (after first-dose revaccination)
Number of subjects: 228
Study 25567010 — intervention group
Group type: COMPARATOR
Intervention: Control group (after third-dose revaccination)
Number of subjects: 228
Study 25567010 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-HBc alone (after third-dose revaccination)
Number of subjects: 228
Study 22873342 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe vera gruel (30-40 mL daily)
Number of subjects: 30
Study 22873342 — intervention group
Group type: COMPARATOR
Intervention: Antiretroviral drugs
Number of subjects: 30
Study 20415082 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation (3 times a week for 3 weeks)
Number of subjects: 70
Study 20415082 — intervention group
Group type: COMPARATOR
Intervention: Traction (5 to 6 kg, 20 minutes each time, once every other day) and Nimodipine (40 mg, 3 times a day for 3 weeks)
Number of subjects: 70
Study 17903344 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake of 600 mg
Number of subjects: 12
Study 17903344 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake of 1200 mg
Number of subjects: 12
Study 17903344 — intervention group
Group type: COMPARATOR
Intervention: Calcium intake of 0 mg (control)
Number of subjects: 12
Study 15790983 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS)
Number of subjects: 27
Study 15790983 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline FEV1 corrected for gas compression (NFEV1)
Number of subjects: 27
Study 15790983 — intervention group
Group type: EXPERIMENTAL
Intervention: Rle and maximum transpulmonary pressure (TP(peak)) during the forced manoeuvre
Number of subjects: 27
Study 12456919 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolyzed protein preterm infant formula (HPF)
Number of subjects: 129
Study 12456919 — intervention group
Group type: COMPARATOR
Intervention: Standard preterm infant formula (SPF)
Number of subjects: 129
Study 10487455 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical mupirocin therapy
Number of subjects: 20
Study 10487455 — intervention group
Group type: COMPARATOR
Intervention: Topical nystatin cream
Number of subjects: 20
Study 8757375 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic suture repair
Number of subjects: 103
Study 8757375 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sutureless repair
Number of subjects: 103
Study 8757375 — intervention group
Group type: COMPARATOR
Intervention: Open suture repair
Number of subjects: 103
Study 8757375 — intervention group
Group type: COMPARATOR
Intervention: Open sutureless repair
Number of subjects: 103
Study 8757375 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic repair (both suture and sutureless)
Number of subjects: 103
Study 8757375 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 103
Study 1465747 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (200 micrograms, one puff twice daily)
Number of subjects: 18
Study 1465747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 6373050 — intervention group
Group type: EXPERIMENTAL
Intervention: Minoxidil
Number of subjects: 17
Study 6373050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31155472 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (IVR) injections
Number of subjects: 32
Study 31155472 — intervention group
Group type: COMPARATOR
Intervention: Healthy control participants
Number of subjects: 32
Study 29369159 — intervention group
Group type: EXPERIMENTAL
Intervention: Tox+ for stimulants (methamphetamine or cocaine)
Number of subjects: 84
Study 29369159 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use severity measured by the Addiction Severity Index
Number of subjects: 84
Study 29369159 — intervention group
Group type: EXPERIMENTAL
Intervention: Tox+ for stimulants
Number of subjects: 84
Study 26663359 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 872
Study 26663359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 872
Study 24561811 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive Exercise (RE)
Number of subjects: 24
Study 24561811 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive Vibration Exercise (RVE)
Number of subjects: 24
Study 24561811 — intervention group
Group type: COMPARATOR
Intervention: Inactive Control Group
Number of subjects: 24
Study 22222478 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-loop control using a proportional-integral-derivative controller
Number of subjects: 61
Study 22222478 — intervention group
Group type: COMPARATOR
Intervention: Skilled manual control of propofol and remifentanil using target-controlled-infusion systems
Number of subjects: 61
Study 20570755 — intervention group
Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 0
Study 18154644 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (TDF)
Number of subjects: 680
Study 18154644 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release oral morphine (SRM)
Number of subjects: 680
Study 18154644 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TDF and SRM
Number of subjects: 680
Study 16217721 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech Therapy Assessment (STA)
Number of subjects: 260
Study 12017395 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 305
Study 12017395 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated diclofenac sodium 50 mg (3 doses of 50 mg every 8 hours)
Number of subjects: 305
Study 12017395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study 10396581 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scanning organization in Italian hospitals
Number of subjects: 179
Study 10396581 — intervention group
Group type: COMPARATOR
Intervention: CT scanning organization in UK hospitals
Number of subjects: 179
Study 7560118 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant-centered intervention using the Brazelton Neonatal Behavioral Assessment Scale (NBAS)
Number of subjects: 0
Study 7560118 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother-centered intervention consisting of an in-depth interview focused on mothers' concerns about parenting
Number of subjects: 0
Study 2142700 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg dexamethasone
Number of subjects: 119
Study 2142700 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg dexamethasone
Number of subjects: 119
Study 2142700 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg dexamethasone
Number of subjects: 119
Study 2142700 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg dexamethasone
Number of subjects: 119
Study 6283873 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary fiber diet
Number of subjects: 8
Study 6283873 — intervention group
Group type: COMPARATOR
Intervention: Low dietary fiber diet
Number of subjects: 8
Study 31382977 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 30 mg/d + standard therapy for 4 days
Number of subjects: 255
Study 31382977 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 255
Study 31382977 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic corticosteroids (in RTP cohort)
Number of subjects: 255
Study 31382977 — intervention group
Group type: EXPERIMENTAL
Intervention: Genes associated with 1-year mortality
Number of subjects: 255
Study 29958284 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry-sheet TBW (DRY group)
Number of subjects: 48
Study 29958284 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet-sheet TBW (WET group)
Number of subjects: 48
Study 26498434 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait rehabilitation for stroke patients with basal ganglia involvement and prior stroke
Number of subjects: 408
Study 26498434 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait rehabilitation for stroke patients with lacunar infarctions
Number of subjects: 408
Study 26498434 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait rehabilitation for stroke patients with right-hemisphere cortical involvement
Number of subjects: 408
Study 24817374 — intervention group
Group type: EXPERIMENTAL
Intervention: SILS sleeve gastrectomy (SG)
Number of subjects: 28
Study 24817374 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic surgery (CLS)
Number of subjects: 28
Study 24817374 — intervention group
Group type: COMPARATOR
Intervention: Both groups (SILS and CLS)
Number of subjects: 28
Study 22364374 — intervention group
Group type: EXPERIMENTAL
Intervention: Rowing (250-270 km · week⁻¹)
Number of subjects: 22
Study 22364374 — intervention group
Group type: COMPARATOR
Intervention: Rowing plus weight-training (190-210 km · week⁻¹ + 4 sessions/week)
Number of subjects: 22
Study 20186890 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 gastrectomy
Number of subjects: 267
Study 20186890 — intervention group
Group type: COMPARATOR
Intervention: D1 gastrectomy
Number of subjects: 267
Study 17505723 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Number of subjects: 41
Study 17505723 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Number of subjects: 41
Study 17505723 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 41
Study 16321619 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alfentanil (23, 30, 43, or 75 microg/kg)
Number of subjects: 20
Study 16321619 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alfentanil
Number of subjects: 20
Study 16321619 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam
Number of subjects: 20
Study 16321619 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous midazolam
Number of subjects: 20
Study 16321619 — intervention group
Group type: COMPARATOR
Intervention: Control (no CYP3A modulation)
Number of subjects: 20
Study 16321619 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (intestinal CYP3A inhibition)
Number of subjects: 20
Study 16321619 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (CYP3A induction)
Number of subjects: 20
Study 16321619 — intervention group
Group type: EXPERIMENTAL
Intervention: Troleandomycin (CYP3A inhibition)
Number of subjects: 20
Study 11986452 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam plus oral transmucosal fentanyl (5-10 microg/kg)
Number of subjects: 51
Study 11986452 — intervention group
Group type: COMPARATOR
Intervention: Oral midazolam plus placebo
Number of subjects: 51
Study 11986452 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam plus oral transmucosal fentanyl
Number of subjects: 51
Study 9535154 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg urapidil orally
Number of subjects: 40
Study 9535154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7893017 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybuprocaine 0.4%
Number of subjects: 90
Study 7893017 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 4%
Number of subjects: 90
Study 7893017 — intervention group
Group type: COMPARATOR
Intervention: Balanced Salt Solution (BSS)
Number of subjects: 90
Study 7893017 — intervention group
Group type: COMPARATOR
Intervention: Oxybuprocaine (3 drops)
Number of subjects: 90
Study 7893017 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybuprocaine with cotton tip sticks
Number of subjects: 90
Study 2761587 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (500 mg daily)
Number of subjects: 3069
Study 2761587 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (1300 mg daily)
Number of subjects: 3069
Study 323326 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronkosol
Number of subjects: 0
Study 323326 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoetharine
Number of subjects: 0
Study 323326 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine
Number of subjects: 0
Study 323326 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronkosol and Isoetharine
Number of subjects: 0
Study 323326 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine added to Isoetharine
Number of subjects: 0
Study 323326 — intervention group
Group type: COMPARATOR
Intervention: Bronkosol, Isoetharine, and Phenylephrine
Number of subjects: 0
Study 30855691 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mood induction
Number of subjects: 0
Study 30855691 — intervention group
Group type: COMPARATOR
Intervention: Neutral mood induction
Number of subjects: 0
Study 28445631 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT with Exposure Therapy (CBT/Exposure)
Number of subjects: 80
Study 28445631 — intervention group
Group type: COMPARATOR
Intervention: CBT without Exposure Therapy (CBT)
Number of subjects: 80
Study 26081486 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose-sweetened soft drinks (SSSDs) - 1 l daily for 6 months
Number of subjects: 47
Study 26081486 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric semi-skimmed milk - 1 l daily for 6 months
Number of subjects: 47
Study 26081486 — intervention group
Group type: COMPARATOR
Intervention: Diet cola - 1 l daily for 6 months
Number of subjects: 47
Study 26081486 — intervention group
Group type: COMPARATOR
Intervention: Water - 1 l daily for 6 months
Number of subjects: 47
Study 23820464 — intervention group
Group type: EXPERIMENTAL
Intervention: Current cannabis users (n=18)
Number of subjects: 87
Study 23820464 — intervention group
Group type: COMPARATOR
Intervention: Past cannabis users (n=33)
Number of subjects: 87
Study 23820464 — intervention group
Group type: COMPARATOR
Intervention: Never cannabis users (n=36)
Number of subjects: 87
Study 21629012 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignette describing a character with alcoholism
Number of subjects: 0
Study 21629012 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignette describing a character with depression
Number of subjects: 0
Study 21629012 — intervention group
Group type: COMPARATOR
Intervention: Vignette describing a character with schizophrenia
Number of subjects: 0
Study 21629012 — intervention group
Group type: COMPARATOR
Intervention: Vignette describing a character with minor problems
Number of subjects: 0
Study 19786163 — intervention group
Group type: EXPERIMENTAL
Intervention: Online risk assessment + feedback
Number of subjects: 168
Study 19786163 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 168
Study 19786163 — intervention group
Group type: EXPERIMENTAL
Intervention: Online risk assessment + feedback (high-risk subjects)
Number of subjects: 168
Study 19786163 — intervention group
Group type: COMPARATOR
Intervention: Control (high-risk subjects)
Number of subjects: 168
Study 16699126 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education module (5 sessions)
Number of subjects: 703
Study 15338971 — intervention group
Group type: EXPERIMENTAL
Intervention: 81 mg/day aspirin
Number of subjects: 22
Study 15338971 — intervention group
Group type: EXPERIMENTAL
Intervention: 325 mg/day aspirin
Number of subjects: 22
Study 15338971 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril
Number of subjects: 22
Study 15338971 — intervention group
Group type: COMPARATOR
Intervention: baseline (no aspirin)
Number of subjects: 22
Study 11341854 — intervention group
Group type: EXPERIMENTAL
Intervention: naloxone/lofexidine combination treatment
Number of subjects: 49
Study 11341854 — intervention group
Group type: COMPARATOR
Intervention: lofexidine monotherapy
Number of subjects: 49
Study 9403155 — intervention group
Group type: EXPERIMENTAL
Intervention: Alexithymics
Number of subjects: 24
Study 9403155 — intervention group
Group type: COMPARATOR
Intervention: Non-alexithymics
Number of subjects: 24
Study 9403155 — intervention group
Group type: COMPARATOR
Intervention: TAT card II
Number of subjects: 24
Study 8216441 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg/d
Number of subjects: 56
Study 8216441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 8216441 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 56
Study 3109670 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined clinic with a rheumatologist and an orthopaedic surgeon
Number of subjects: 0
Study 3109670 — intervention group
Group type: COMPARATOR
Intervention: Orthopaedic clinic with an orthopaedic surgeon alone
Number of subjects: 0
Study 28895379 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at a target effect‐site concentration of 7 ng×mL‐1
Number of subjects: 120
Study 28895379 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline SPI value in patients without pain
Number of subjects: 120
Study 28895379 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal SPI value after intubation in patients receiving remifentanil
Number of subjects: 120
Study 27282158 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg liraglutide
Number of subjects: 60
Study 27282158 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 mg liraglutide
Number of subjects: 60
Study 27282158 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 mg liraglutide
Number of subjects: 60
Study 27282158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 24566596 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional Care Clinic (TCC)
Number of subjects: 100
Study 24566596 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 23942318 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (MT) plus treatment as usual (TAU)
Number of subjects: 144
Study 23942318 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) alone
Number of subjects: 144
Study 24843430 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes prevalence in 2003
Number of subjects: 1806
Study 24843430 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes prevalence in 2008
Number of subjects: 1806
Study 24843430 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediabetes prevalence in 2003
Number of subjects: 1806
Study 24843430 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediabetes prevalence in 2008
Number of subjects: 1806
Study 24843430 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes incidence rate
Number of subjects: 1806
Study 24843430 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediabetes incidence rate
Number of subjects: 1806
Study 24843430 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor - Impaired fasting glucose (IFG)
Number of subjects: 1806
Study 24843430 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor - Impaired glucose tolerance (IGT)
Number of subjects: 1806
Study 24843430 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor - Age
Number of subjects: 1806
Study 24843430 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor - Waist-to-hip ratio
Number of subjects: 1806